Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
Androgen-deprivation therapy is the mainstay of treatment for the management of advanced prostate carcinoma till transition to castration-resistant prostate carcinoma (CRPC). Recently, adrenal and intratumoral synthesis of androgens has been found to be the major cause for CRPC. Abiraterone acetate...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
| Series: | Journal of Postgraduate Medicine |
| Subjects: | |
| Online Access: | http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2012;volume=58;issue=3;spage=203;epage=206;aulast=Nandha |